Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Puts Faith In Late-Stage Assets In Hopes Of Profit Growth In 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly is making major bets on the oncology and diabetes drugs in its late-stage pipeline in hopes that these assets will fill the hole left by Zyprexa, and soon Cymbalta.

Advertisement

Related Content

Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings
Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings
Deals Of The Week: Idenix/Janssen, Genentech/Afraxis, Immunomedics/Algeta
Emerging Markets Earnings Roundup: Pfizer, Lilly (Part 2)
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Ramucirumab Becomes First Lilly ImClone Compound To Enjoy Phase III Success
New Long-Acting Insulin Offerings Could Derail Lantus Franchise

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel